1. Pink Sheet
  2. >>Vaccines

US FDA Wants Global COVID-19 Vaccine Update System, But Says May Not Be Possible

 
• By Derrick Gingery

The agency’s Vaccines and Related Biological Products Advisory Committee will consider simplifying and harmonizing the vaccine composition, as well as formalizing a system for likely annual US updates.

COVID-19 vaccine vials
Simplifying the COVID-19 vaccine composition could reduce the number of vials providers must have on hand. • Source: Shutterstock

US Food and Drug Administration officials could make changes to the COVID-19 vaccines independent of other countries or regions going forward rather than relying on a coordinated global effort.

The FDA’s Vaccines and Related Biological Products Advisory Committee will discuss whether COVID-19 vaccines should be updated annually with new strains as the virus evolves during a 26 January meeting, which the agency is positioning as a coming-out event for the idea of annual COVID shots

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.